Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
08/2003
08/07/2003WO2003030829A3 Liposome-encapsulated insulin formulations
08/07/2003WO2003028662A3 A method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
08/07/2003WO2003015782A3 Receptor-adapted nicotine withdrawal by anti-cholinergic and anti-noradrenergic blockage
08/07/2003WO2003011212A3 Biodegradable polyhydric alcohol esters
08/07/2003WO2002094228A8 Prevention and treatment of allergies by helminthic regulation of ige
08/07/2003WO2002056932A3 Thermal vaporizing device for drug delivery
08/07/2003WO2002049610A3 Ophthalmic irrigating solution adapted for use in lasik surgery
08/07/2003WO2002009709A8 Method for reducing or eliminating smoking
08/07/2003US20030149470 Radially expandable; coaxial polymer comprising pentafluoropropyl acrylate and (heptadecyl fluorodecyl methacrylate) comonomers
08/07/2003US20030149423 Methods for the detection and treatment of cardiac events
08/07/2003US20030149420 Method and apparatus for treating bodily tissues with medicinal substance
08/07/2003US20030149406 One polyurethane foam layer has therapeutic drug dispersed in, outer covering layer is polyurethane hydrogel, and a drug-free polymer layer; cooling properties, wound healing
08/07/2003US20030149385 Ultraviolet-schielding adhesive preparation
08/07/2003US20030149383 Patch containing anti-inflammatory agent
08/07/2003US20030149296 Such as 3-(4-salicyloylamino)phenoxypropionic acid; noncovalent drug delivery
08/07/2003US20030149128 Stabilized monomer adhesive compositions
08/07/2003US20030149113 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
08/07/2003US20030149111 For therapy of diabetes, hyperglycemia
08/07/2003US20030149106 For use in moisturizing compositions (e.g., moisturizing skin treatments) to which medical adhesives will adhere, in tissue antiseptic preparations, in personal care forumulation such as cosmetics, and in drug delivery forumulations
08/07/2003US20030149100 Clear micellized formulations of beta-carotene and method of treating leukoplakia
08/07/2003US20030149098 Clear micellized formulations of beta-carotene and method of treating leukoplakia
08/07/2003US20030149090 Topically delivering an effective dose of a reactvie oxygen metabolites (ROM) production and release inhibitory compound in carrier to a subject suffering from ROM-mediated oxidative damage
08/07/2003US20030149075 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
08/07/2003US20030149061 Oily compositions containing highly fat-soluble drugs
08/07/2003US20030149012 Vision through photodynamic therapy of the eye
08/07/2003US20030149009 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
08/07/2003US20030149008 Hormonal implants treatment of the breast cancer
08/07/2003US20030149007 For inducing bronchodilation or providing relief of bronchospasm
08/07/2003US20030148996 For therapy of undesirable or uncontrolled cell proliferation
08/07/2003US20030148992 Designed to release therapeutic material at different rate(s) after ingestion
08/07/2003US20030148990 Administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist for therapy of hypersecretion of mucus in lungs
08/07/2003US20030148985 Methods and reagents for the inhibition of hepatitis B virus replication
08/07/2003US20030148974 Antisense modulation of akt-3 expression
08/07/2003US20030148948 Super-active porcine growth hormone releasing hormone analog
08/07/2003US20030148941 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
08/07/2003US20030148931 A drug delivery system (DDS) compound of a carboxylated polysaccharide derivative bonded to a camptothecin derivative with or with out a oligopeptide a spacer; storage stability; preservation; side effect reduction; antitumor agents
08/07/2003US20030148925 Insulin formulation for inhalation
08/07/2003US20030148577 Controlled alignment of catalytically grown nanostructures in a large-scale synthesis process
08/07/2003US20030148099 Microcapsules having high carotenoid content
08/07/2003US20030147975 Pharmaceutical composition which produces irritation
08/07/2003US20030147970 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
08/07/2003US20030147968 Allantoin-containing preparations for administration as gels and aerosols
08/07/2003US20030147967 Apparatus and method for preparing microparticles
08/07/2003US20030147966 Nanoparticle delivery vehicle
08/07/2003US20030147965 Methods and products useful in the formation and isolation of microparticles
08/07/2003US20030147964 Storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres for sustained release and
08/07/2003US20030147962 A lipid or other hydrophobic or amphiphilic compound is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as
08/07/2003US20030147961 Solid dose delivery vehicle and methods of making same
08/07/2003US20030147959 Alpha-tocopherol, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans various routes is disclosed. Polyoxyethylene
08/07/2003US20030147957 An inner core formulated for controlled release comprising a mixture of a granulated admixture of a decarboxylase inhibitor and a surfactant, and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof;immediate release
08/07/2003US20030147956 Biodegradable bioadhesive controlled release system of nano-particles for oral care products
08/07/2003US20030147955 Dry .1 to 1.5% tamsulosin active material and excipients; treating benign prostatic hyperplasia
08/07/2003US20030147954 Cyclosporin and a release modifier encapsulated in a biodegradable polymer
08/07/2003US20030147953 Multiple delayed release dosages forms that each have different release profiles, with maximum concentration of the product being reached in < 12 hours
08/07/2003US20030147952 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
08/07/2003US20030147951 Tablet composition
08/07/2003US20030147950 .1-10 mg of tamsulosin with an enteric coating and has a dissolution profile in media of </= 60% at 2 hours; reduced or no food effect
08/07/2003US20030147949 Slurry of wet cake microcrystalline cellulose and silicon dioxide of particle size 1nm-100 mu m, drying, mixing with an active ingredient and compressing
08/07/2003US20030147948 Composition comprises sustained-release fine particles and manufacturing method thereof
08/07/2003US20030147947 Orodispersible solid pharmaceutical form
08/07/2003US20030147946 Aqueous dispersions of crystalline polymers and uses
08/07/2003US20030147945 Vehicles stably associated with non-antagonistic combinations of >/= 2 synergistic agents
08/07/2003US20030147944 Outer leaflet of hydrophilic polymer-lipid conjugates that have a reactive surface; reduced interaction with macromolecules and increased blood circulation time
08/07/2003US20030147943 Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
08/07/2003US20030147942 Pharmaceutical gel composition
08/07/2003US20030147936 Prostatic hormonal implants treatment of prostate cancer
08/07/2003US20030147930 Antibiotic, functional cosmetic and functional food containing levulinic acid and their derivatives
08/07/2003US20030147927 Eutectic-based self-nanoemulsified drug delivery system
08/07/2003US20030147926 Compositions and methods for transdermal oxybutynin therapy
08/07/2003US20030147898 Adjuvant formulation comprising a submicron oil droplet emulson
08/07/2003US20030147889 Administering type 1-interferon antibody, for inhibition of prevention of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis and psoriasis
08/07/2003US20030147849 Topical formulations for delivery of interleukin-11
08/07/2003US20030147835 Process for the manufacture of hydrogel compositions and hydrogel compositions manufactured thereby
08/07/2003US20030147815 Administering tri-(or tetra-)iodothyropropionic acid
08/07/2003US20030147814 Medicinal aerosol formulations comprising ion pair complexes
08/07/2003US20030146530 Zero order release and temperature-controlled microcapsules and process for the preparation thereof
08/07/2003US20030146311 Method for producing nanometer micro-powder of natural materials and products of the method
08/07/2003US20030145854 Apparatuses and methods for automatically assessing and monitoring a patient's responsiveness
08/07/2003US20030145850 Metered dose inhaler
08/07/2003US20030145786 Device for the coating of granulates and seeds
08/07/2003CA2474958A1 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
08/07/2003CA2474835A1 Immediate release dosage forms containing solid drug dispersions
08/07/2003CA2474809A1 Dry granulated formulations of azithromycin
08/07/2003CA2474723A1 Bioactive keratin peptides
08/07/2003CA2474711A1 Responsive microgel and methods related thereto
08/07/2003CA2474710A1 Freeze-dried pharmaceutically acceptable inclusion complexes of propofol and cyclodextrin
08/07/2003CA2474690A1 Composition for inhalation
08/07/2003CA2474588A1 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
08/07/2003CA2474571A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
08/07/2003CA2474487A1 Photovoltaic cell interconnection
08/07/2003CA2474447A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors
08/07/2003CA2474425A1 Osmotic delivery system
08/07/2003CA2474387A1 Isotropic transparent compositions containing fat soluble vitamin
08/07/2003CA2474349A1 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
08/07/2003CA2472342A1 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
08/07/2003CA2472242A1 Cyclosporin-containing sustained release pharmaceutical composition
08/07/2003CA2472103A1 Transmucosal delivery of proton pump inhibitors
08/07/2003CA2470256A1 Medicated tampon
08/07/2003CA2469571A1 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
08/07/2003CA2466228A1 Method for treating diseases with omega interferon
1 ... 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 ... 2991